Friday Policy Updates 1/12/2018

Friday, January 12, 2018

Continue Reading

RxRevu Unveils New SwiftRx® Platform at 36th Annual J.P.Morgan Healthcare Conference

Wednesday, January 10, 2018

RxRevu, the industry leader in Prescription Decision Support, will unveil its new SwiftRx® platform while attending the 36th Annual J.P.Morgan Healthcare Conference on January 8th in San Francisco, CA. Building on RxRevu’s proven success, this unique and revolutionary platform helps doctors choose which drug to prescribe through a proprietary guidance-based approach that considers the patients real-time cost and evidence-based clinical recommendations. The SwiftRx® platform is also the first to prospectively complete electronic prior authorizations (ePA) for prescriptions, eliminating a huge frustration of providers that has plagued the industry for years. 

miRagen: Comprehensive, microRNA Targeted Therapies

Tuesday, January 09, 2018


Inocucor Raises $9.5 Million in Series B Second Close Led by Pontifax AgTech, Raising Total Proceeds of Series B Financing to $38.5 Million

Monday, January 08, 2018

Inocucor Raises $9.5 Million USD ($12.1 Million CAD) in Series B Second Close Led by Pontifax AgTech, Raising Total Proceeds of Series B Financing to $38.5 Million USD ($50.9 Million CAD) 


Monday, January 08, 2018

Articulus Bio, LLC, a development-stage orthopedic medical device platform focused on total joint replacement, today announced that Adam B. Rubenstein, Chief Executive Officer, will present at the 10th annual Biotech Showcase Conference on Wednesday, January 10, 2018, at 3:15 p.m. PST. The conference is being held at the Hilton Union Square Hotel in San Francisco, California.  

Friday Policy Updates – 1/5/2018

Friday, January 05, 2018

Under the Gold Dome – The 71st General Assembly
Continue Reading

Millennials in Colorado

Wednesday, January 03, 2018


At the Center of Everything

Tuesday, December 19, 2017


Ampio Pharmaceuticals Reports Positive Results for both Primary and Secondary Endpoints of Pivotal Phase 3 Trial of Ampion™ in Severe Osteoarthritis-of-the Knee (OAK)

Friday, December 15, 2017

  • Primary endpoint of OMERACT-OARSI responder rate at 12 weeks achieved statistical significance (p < 0.001)
  • Ampion™ is the first therapy indicated for signs and symptoms for severe osteoarthritis of the knee and will address a significant treatment gap
  • Conference call, December 14, at 6:30 a.m. MT (8:30 ET)

ENGLEWOOD, Colo., December 14, 2017Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today reported that the Phase 3 clinical trial of Ampion™ met its primary endpoint with 71% of Ampion™ treated patients meeting the OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee (p < 0.001). Responders experienced, on average a 53% decrease in pain as measured by WOMAC A and a 50% improvement in function as measured by WOMAC C and a 45% improvement in quality of life as measured by Patient Global Assessment (PGA). In the secondary endpoints, Ampion™ treated patients achieved statistical significance in a composite endpoint of pain and function from baseline in both categories at 12 weeks (p < 0.001), which was supported by an increase in quality of life as measured by patient global assessment (PGA) (p < 0.001). When treated with Ampion™ (n=144), patients experienced significant improvement in a composite endpoint of pain and function compared to all KL 4 saline-treated patients (n=206) in Ampion™ phase 3 clinical trials (p < 0.001).

If approved, Ampion™ would be the first intra-articular injection to treat the signs and symptoms of patients with severe osteoarthritis of the knee (Kellgren-Lawrence x-ray grade 4). In order to support a label for signs and symptoms, Ampion™ was asked to demonstrate clinical efficacy in a composite response of pain, function and be supported by quality of life.

Ampion™ was well tolerated with treatment-emergent adverse events (TEAEs) comparable to those of placebo in all single-injection studies of Ampion™. There were no drug-related serious TEAEs associated with the Ampion™ arm. The safety and tolerability profile of Ampion™ is consistent with previous studies. To date, Ampion™ has been given to over 900 patients with no reported drug-related serious TEAEs.

Ampio plans to present a more detailed analysis of the Phase 3 and pooled data at an upcoming scientific meeting as well as submission for publication.

Conference Call

At 8:30 a.m. ET Ampio's management will host a conference call to discuss the Phase 3 clinical results. The dial-in number for the conference call is (877) 260-1479 for U.S./Canada participants and (334) 323-0522 for local participants, with Participant Passcode # 6638480. A live webcast of the conference call can also be accessed through the "Investors" tab on the Ampio Pharmaceuticals website at A webcast replay will be available online after the call.

“We are very pleased with the positive Phase 3 data as we believe that Ampion™ will address an unmet medical need, providing severely diseased patients a non-opioid option that not only reduces pain, but also improves function and quality of life in a meaningful way” said Michael Macaluso, Chairman and CEO, Ampio Pharmaceuticals. “We are hopeful that Ampion™ will serve as a safe and effective treatment for an incurable, progressive disease that afflicts 21 million people in the U.S. and over 200 million people worldwide who suffer from osteoarthritis. We look forward to working closely with the U.S. Food and Drug Administration (FDA) as we prepare to submit our Biologics License Application (BLA) for Ampion.”

In this multi-center, randomized study of 144 KL4 patients with severe OAK of the knee, patients received either a single 4mL intra-articular injection of Ampion™ or placebo at a ratio of 6:1. The primary endpoint of responder analysis using OMERACT-OARSI was evaluated at 12-weeks following a single injection.

The OMERACT-OARSI response composite looks to assess three core symptoms of OAK (pain, function, and patient’s global assessment) as a single variable. For each domain, a response requires both a relative and an absolute change. OMERACT-OARSI response is defined as having a high improvement in pain or function and/or a clinically meaningful improvement in two of three core measurements of OA: pain, function or quality of life. Specifically, to be considered a responder, a patient must demonstrate improvement in WOMAC A (pain) or WOMAC C (function) of ≥50% and absolute change of ≥1.0 point on a 5 point Likert (0-4) scale, or ≥20% improvement in at least 2 of the following 3 categories: WOMAC A, WOMAC C, or Patient Global Assessment, with a 0.5 point change on a 5 point (0-4) pain scale.

Continue Reading

Denver Business Journal Recognizes Colorado BioScience's Remarkable Year!

Thursday, December 14, 2017

The Denver Business Journal wants their readers to know the bioscience industry in our state has enjoyed a record breaking year.